Sign up to access all valuation multiples
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
2003
107
LTM Revenue $195M
LTM EBITDA $113M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of December 2025, BioArctic reported last 12-month revenue of $195M and EBITDA of $113M.
In the same period, BioArctic generated $190M in LTM gross profit and $93.4M in net income.
See BioArctic valuation multiples based on analyst estimatesIn the most recent fiscal year, BioArctic reported revenue of $28.0M and EBITDA of -$19.5M.
BioArctic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioArctic valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $195M | XXX | $28.0M | XXX | XXX | XXX |
| Gross Profit | $190M | XXX | $25.1M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $113M | XXX | -$19.5M | XXX | XXX | XXX |
| EBITDA Margin | 58% | XXX | -69% | XXX | XXX | XXX |
| EBIT | $113M | XXX | -$25.0M | XXX | XXX | XXX |
| EBIT Margin | 58% | XXX | -89% | XXX | XXX | XXX |
| Net Profit | $93.4M | XXX | -$19.3M | XXX | XXX | XXX |
| Net Margin | 48% | XXX | -69% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioArctic has current market cap of SEK 29.2B (or $3.2B), and EV of SEK 27.3B (or $3.0B).
As of January 16, 2026, BioArctic's stock price is SEK 329 (or $36).
See BioArctic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.2B | XXX | XXX | XXX | XXX | $1.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialBioArctic's trades at 15.2x EV/Revenue multiple, and 26.3x EV/EBITDA.
See valuation multiples for BioArctic and 15K+ public compsAs of January 16, 2026, BioArctic has market cap of $3.2B and EV of $3.0B.
Equity research analysts estimate BioArctic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioArctic has a P/E ratio of 34.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 15.2x | XXX | 15.2x | XXX | XXX | XXX |
| EV/EBITDA | 26.3x | XXX | 26.3x | XXX | XXX | XXX |
| EV/EBIT | 26.4x | XXX | 26.4x | XXX | XXX | XXX |
| EV/Gross Profit | 15.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 34.0x | XXX | 34.0x | XXX | XXX | XXX |
| EV/FCF | 17.5x | XXX | 17.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioArctic's last 12 month revenue growth is -33%
BioArctic's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
BioArctic's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioArctic's rule of X is -24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioArctic and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -33% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 58% | XXX | 58% | XXX | XXX | XXX |
| EBITDA Growth | -62% | XXX | 88% | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 121% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 179% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioArctic acquired XXX companies to date.
Last acquisition by BioArctic was XXXXXXXX, XXXXX XXXXX XXXXXX . BioArctic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was BioArctic founded? | BioArctic was founded in 2003. |
| Where is BioArctic headquartered? | BioArctic is headquartered in Sweden. |
| How many employees does BioArctic have? | As of today, BioArctic has 107 employees. |
| Who is the CEO of BioArctic? | BioArctic's CEO is Dr. Gunilla Osswald. |
| Is BioArctic publicy listed? | Yes, BioArctic is a public company listed on STO. |
| What is the stock symbol of BioArctic? | BioArctic trades under BIOA B ticker. |
| When did BioArctic go public? | BioArctic went public in 2017. |
| Who are competitors of BioArctic? | Similar companies to BioArctic include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of BioArctic? | BioArctic's current market cap is $3.2B |
| What is the current revenue of BioArctic? | BioArctic's last 12 months revenue is $195M. |
| What is the current revenue growth of BioArctic? | BioArctic revenue growth (NTM/LTM) is -33%. |
| What is the current EV/Revenue multiple of BioArctic? | Current revenue multiple of BioArctic is 15.2x. |
| Is BioArctic profitable? | Yes, BioArctic is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioArctic? | BioArctic's last 12 months EBITDA is $113M. |
| What is BioArctic's EBITDA margin? | BioArctic's last 12 months EBITDA margin is 58%. |
| What is the current EV/EBITDA multiple of BioArctic? | Current EBITDA multiple of BioArctic is 26.3x. |
| What is the current FCF of BioArctic? | BioArctic's last 12 months FCF is $170M. |
| What is BioArctic's FCF margin? | BioArctic's last 12 months FCF margin is 87%. |
| What is the current EV/FCF multiple of BioArctic? | Current FCF multiple of BioArctic is 17.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
